Glaxosmithkline Plc: (NYSE: GSK)
$52.44
0.72 (1.39%)
Volume 1,946,517
May 15 03:47 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 52.08 - 52.53 |
| 52wk Low - High | 41.68 - 52.54 |
| Previous Close | 51.72 |
| Avg. Volume | 3,149,940 |
| Industry | LARGE CAP PHARMA |
| Market Cap | 126.82 B |
| Div - Yield | 2.20 - 4.26 |
| Beta | 0.64 |
| PE (Forward) | 14.20 |
| Current Year Est. | 3.64 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
170 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 14.20 |
| PEG Ratio | 2.14 |
| Current Year Est. | 3.64 |
| Current Quarter Estimate | 0.88 |
| Most Accurate Estimate | 0.88 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 07-24-2013 |
| EPS Last Year | 3.53 |
| Expected Earnings Growth | 6.62% |
Company Description
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.88 | 0.91 | 3.64 | 4.02 |
| Number of Estimates | 2 | 2 | 7 | 6 |
| Low Estimate | 0.88 | 0.88 | 3.60 | 3.78 |
| High Estimate | 0.89 | 0.93 | 3.79 | NA |
| Year Ago EPS | 0.82 | 0.85 | 3.58 | 3.64 |
| EPS Growth | 7.93% | 6.47% | 1.76% | 10.26% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| GLAXOSMITHKLINE | GSK | 51.72 | |
|
| ABBOTT LABS | ABT | 37.05 | |
|
| ABBVIE INC | ABBV | 45.35 | |
|
| ALLERGAN INC | AGN | 103.78 | |
|
| ASTRAZENECA PLC | AZN | 51.19 | |
|
| BRISTOL-MYERS | BMY | 42.21 | |
|
| JOHNSON & JOHNS | JNJ | 86.97 | |
|
| LILLY ELI & CO | LLY | 55.87 | |
|
| MERCK & CO INC | MRK | 46.65 | |
|
| NOVARTIS AG-ADR | NVS | 74.59 | |
|
Sector:Medical>> Industry:LARGE CAP PHARMA
COMPARE TICKER vs. Its Peers
Zacks Commentary
Elan in Royalty Deal with THRX
May 14, 2013
Wider-than-Expected Loss at ChemoCentryx
May 14, 2013
Glaxo/THRX's Breo Ellipta Gets FDA Nod
May 13, 2013
Isis Reports In-Line Loss
May 08, 2013
Wider-than-Expected Loss at Dynavax
May 07, 2013
Glaxo's Trametinib Delayed
May 02, 2013
Impax Beats Earnings Estimate
May 02, 2013
Stocks Market News for May 1, 2013
May 01, 2013
Financials
| EPS TTM | 3.53 |
| Sales | 41,896 |
| Net Income | 6,624 |
| Price/Earnings | 14.65 |
| Price/Book | 10.72 |
| Price/Cash Flow | 12.08 |
| Price/Sales | 3.06 |
News
Analyzing the Global CNS Market: 2013 Edition - M2
May 15, 2013
Aveo Screwed Up But Its Kidney Cancer Drug Is Real - TheStreet.com
May 15, 2013
Aveo Screwed Up but Its Kidney Cancer Drug Is Real - TheStreet.com
May 15, 2013
Cervical Cancer Vaccine for Girls On Cards - All Africa Global Media
May 15, 2013
GlaxoSmithKline PLC (GSK) Showing Bullish Technicals With Support At $51.39 - Freshbrewedmedia
May 15, 2013
Is AstraZeneca Gearing Up for a Shopping Spree? - TheMotleyFool
May 15, 2013
Theravance Looks to Reward Shareholders by Splitting Into Two Distinct Companies - TheMotleyFool
May 15, 2013
WNS extends contract with GlaxoSmithKline for research and analytics services - Datamonitor
May 15, 2013
Broker Recommendations
| Current ABR | 3.00 |
| ABR (Last Week) | 2.82 |
| # of recs in ABR | 10 |
| Average Target Price | 49.69 |
| Industry Rank by ABR | 170 out of 265 |
| Rank in Industry | 1 out of 15 |
